



NIST Medical Imaging Informatics Activities

Ram Sriram
Mary Brady
Alden Dima

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce



Medical Imaging

- Biomarker Testing
 - Improving Change Analysis in Lung Cancer
 - Statistically Valid and Clinically Meaningful Biomarkers
- Metrics for Image Quality
 - QIBA 1C: Scanner Variability
 - Reducing Dose through Iterative Reconstruction
- Semantic Interpretation
 - Interpreting Wireless Capsule Endoscopy Images
 - From Images to Diagnosis through Ontologies

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce

Collaborations

Logos include: GIYEN IMAGING, FDA, Carnegie Mellon, INSTITUTE FOR GENOME SCIENCES University of Maryland School of Medicine, Material Measurement Laboratory, Quantitative Imaging Biomarkers Alliance, CoreLab PARTNERS, Duke UNIVERSITY, PHILIPS, SIEMENS, TOSHIBA, Buckler Biomedical Sciences LLC (BBMSC), RSNA, UMIACS, JIMRC, NATIONAL CANCER INSTITUTE, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, UNIVERSITY OF MARYLAND MEDICAL CENTER, caBIG, Kitware, Physical Measurement Laboratory, GE, and P&L.

Cancer Statistics

2009 Estimated US Cancer Deaths*

	Men	Women
Lung & bronchus	30%	26%
Prostate	9%	15%
Colon & rectum	9%	9%
Pancreas	6%	6%
Leukemia	4%	5%
Liver & intrahepatic bile duct	4%	4%
Esophagus	4%	3%
Urinary bladder	3%	3%
Non-Hodgkin lymphoma	3%	2%
Kidney & renal pelvis	3%	2%
All other sites	25%	25%



ONS=Other nervous system.
Source: American Cancer Society, 2009.

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce



BIOMARKERS

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce




Biomarker Testing

- Improve existing biomarkers and support the development of new ones
- Characterize uncertainty in lesion change measurements across sizing methods and implementations
- Develop informatics and process-based biomarker framework supporting
 - Efficient and economical development
 - Validation
 - Regulatory approval

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce

Medical Imaging *Improving Change Analysis in Lung Cancer*



RECIST : *Response Evaluation Criteria in Solid Tumors*

Complete	Partial	Progressive	Stable
Disappear	30% decrease	20% increase	Small change

NIST Role

- Provide a measurement infrastructure that enables quantifiable and reproducible measurements of tumors
- Develop reference material, measurements and metrics to compare sizing algorithms to ground truth

7

NIST Biochange: *Improving Change Analysis in Lung Cancer*

Target: Late stage lung cancer patients

Biochange '08 Pilot:

- Thick-slice (5 mm) studies
- NCI's RIDER + FDA phantoms
- Radiologists (2) RECIST markup
- Retrospective analysis to obtain additional diameter and volume measurements



Biochange Challenge:


- Thin-slice (1.25, 2.50 mm) ★ NEW
- 56 Clinical, *NCI RIDER*
- 16 Coffee Break, *NCI RIDER*
- 8 Computational Implants, *NIST Peskin*
- 16 Physical Phantoms, *NIST Levine*
- 7 institutions have declared they plan to participate & we're still recruiting



Ellipsoids
Physical Phantoms


	< 30%	30-0%	0-20 %	> 20%
Clinical	8	24	16	8
Coffee Break	0	8	8	0
Synthetic			8	
Ellipsoids			8	8

Biochange: 96 Lesion Pairs



Synthetic
Computational Implants

<http://www.nist.gov/itl/iad/dmg/biochangechallenge.cfm>



Statistically Valid and Clinically Relevant Biomarkers

- Quantitative results from imaging methods have the potential to be used as biomarkers in both routine clinical care and in clinical trials
- When used as biomarkers in therapeutic trials, imaging methods have the potential to speed the development of new products to improve patient care
- Regulatory approval for clinical use and regulatory qualification for research use depend on demonstrating proof of performance relative to the intended application of the biomarker
- NIST is collaborating with RSNA/QIBA, NCI caBIG, and FDA leaders to identify methods and prototype a measurement infrastructure to support biomarker validation


Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce

Validating Biomarkers Proposed Architecture and Design



Goal


- Validation assessment of quantitative imaging biomarker technical and clinical performance via high-throughput computing



Technologies

Technologies	Description
NBIA	Open source, federated grid-based image sharing
Algorithm Validation Toolkit	Analyzing annotation variability to validate medical image processing algorithms
MIDAS	Open source, digital archiving system supporting distributed processing
BatchMake	Cross platform batch processing tool for Big Data


Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce



Architecture

Architectural Issue	Technical Approach
Profile Editor	MIDAS extended to support XML files created by QIBA
Data Management	NBIA is main resource for datasets; MIDAS serves as a proxy to avoid downloading large datasets during experiments
Computation	MIDAS as interface for workflows and grid of computing jobs
Batch Processing	Profile Editor provides workflow driving remote computing via MIDAS/BatchMake
Validation Tools	Integrate Algorithm Validation Toolkit with BatchMake
Workflow Management	MIDAS is workflow and data manager integrating input data and parameters, processing tools and validation results
Validation Analysis	Statistical analysis via R using interface between R and MIDAS; Extend MIDAS with dashboard for results

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce




Progress to Date

- Define use model and requirements
 - Basic Story Board: Abstracted to facilitate translation to UML
 - Enterprise Use Case: The way most users think
 - System Use Cases: Specific mapping to technical solutions
- Define and build services
 - NBIA/MIDAS integration
 - IHE profile approach
- Apply services for proficiency testing with NIST as a neutral broker
 - NBIA / MIDAS integrated approach configured at NIST
 - Instantiating with QIBA 1C phantom images, NIST phantoms, and computational phantoms
 - Engaged in discussions with Pharma/QIBA/NIST Legal on hosting clinical trial data

http://www.kitware.com/NISTQuantitativeImaging/Wiki/index.php/Main_Page

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce



Contributors



- Investigators:
 - Buckler Biomedical Sciences LLC (BBMSC)
 - Kitware, Inc.
- In collaboration with:
 - Information Technology Laboratory of (ITL) of the National Institute of Standards and Technology (NIST)
 - Quantitative Imaging Biomarker Alliance (QIBA)
 - Imaging Workspace of caBIG
 - Stanford Center for Biomedical Informatics Research (BMIR)

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce



METRICS FOR IMAGE QUALITY

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce





Metrics for Image Quality

- Address image quality issues to reduce uncertainty and improve patient safety
- Characterize the effect of scanners on nodule sizing and compare candidate approaches to developing imaging protocols
- Work with radiologists to determine if
 - Image quality is adversely affected at lower doses
 - Computational techniques can reduce patient risk

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce

QIBA 1C Subgroup Scanner Variability Study

QIBA 1C: Scanner Variability Study

- ACR phantom scanned at multiple sites
- Collaborated with medical physicists to converge on “equivalent” scanning protocols
- Designed study to address scanner variability using FDA and NIST phantoms
- Scanned phantoms across sites
- Ground truth to be provided by CoreLab
- In process of loading image sets into NBIA/MIDAS infrastructure for further analysis

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce


Iterative Reconstruction


Collaboration: UMD School of Medicine, Duke, NIST

- Cadaver imaged with standard does and filtered back projection with decreasing dose up to 73% reduction
- No significant difference in mean reader scores and quantitative measurements of image noise

RSNA 2010

- New study to evaluate iterative reconstruction techniques and compare against back projection







Experimental Design

UMd Medical Center CT Dosage & Iterative Reconstruction Alg. Study
Design 1 Factor List
(siegeldex1factorlist.xls) (2/3/11)

	Factor	C/D	# Levels in		- Setting		+ Setting
			Population	Sample			
X1	CT Dose	Continuous	(0,standard)	2	1/2 Standard		Standard
X2	Image type	Discrete	2	2	Raw		Image Recon
X3	CT Vendor	Discrete	~ 5	2	Phillips		Siemens
X4	Tissue Type	Discrete	~30	2	Soft		Hard
X5	"Patient" Type	Discrete	3	2	Phantom		Cadaver



The central practical question is: "Could the radiation output from the CT scanners across the country be reduced by a significant amount with no discernible degradation in the quality of the diagnostic image that the scanner produces?"

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce



SEMANTIC INTERPRETATION

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce



Semantic Interpretation

- Support clinical decision making by highlighting deviation from normal conditions using endoscopic images and to suggest potential disease
- Use computational and semantic techniques to reduce physician burden with the tedious examination of wireless capsule endoscopy videos
- Develop the necessary semantic infrastructure to manage large medical datasets associated with biomarkers and improve their ability to be used in both clinical and research settings


Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce

Interpreting Wireless Capsule Endoscopy Images


- WCE provides visual images of small bowel
- Searching for abnormalities is a time-consuming, tedious process
- Requires a high level of concentration
- Localization of the capsule is difficult and often inaccurate



Images: courtesy of GivenImaging



From Images to Diagnosis: Using Disease Ontology to Support Clinical Decision Making



- Endoscopic video interpretation involves viewing the video and searching for tissue changes due to diseases such as bleeding, erosion, polyps and many more.
- Because of the huge amount of images to review, the investigation takes a significant amount of time.
- Advanced states of the lines usually give large lesions occurring on the large number of consequent images (video frames).
- In the early states of the illness a focal lesion might be present on only one or few video frames. It is very easy to miss such a lesion during "manual investigation"

*Ram D. Sriram, Eswaran Subrahmanian (CMU), Marcin Kocielak (GR), Mala Ramaiah, MD (GR), Nageshwar Reddy, MD

Software and Systems Division
National Institute of Standards and Technology/U.S. Department of Commerce

